Veterinary Rapid Tests Market Size & Share 2026-2035

Veterinary Rapid Tests Market Size

The global veterinary rapid tests market was valued at USD 953.2 million in 2025 and is projected to reach USD 2.3 billion by 2035, expanding at a compound annual growth rate (CAGR) of 9.1% over the forecast period, according to the latest report published by Global Market Insights Inc.

This growth trajectory is driven by the accelerating transition from centralized laboratory diagnostics to point-of-care testing across a broadening range of veterinary care settings, from hospital-based companion animal practices to field-level livestock operations.

The convergence of structural demand-side forces including urban pet adoption trends, One Health policy momentum, and the declining per-test cost of lateral flow assay technologies is positioning veterinary rapid diagnostics as one of the more resilient and consistently expanding subcategories within the broader animal health sector. The near-term pipeline of product innovations in multiplex detection and cloud-connected reader platforms further supports the case for sustained revenue growth across both established and emerging regional markets

Key Drivers

Drivers Impact Analysis

Growing Companion Animal Population

The expanding global companion animal population continues to generate sustained demand for routine and preventive diagnostic testing. Federal survey data indicates that approximately 70% of U.S. households owned at least one pet as of 2024, with dogs and cats accounting for the majority of the companion animal base. As ownership deepens in urban markets across Asia Pacific and Latin America where middle-class expansion and shifting cultural attitudes toward pet care are driving structural changes in demand the frequency of diagnostic episodes per animal per year is rising alongside consumer willingness to invest in proactive health management. Rapid tests are well-positioned to capture this demand growth, given their accessibility, speed, and comparatively low per-test cost structure relative to full laboratory diagnostic panels.

Increasing Prevalence of Zoonotic Diseases

The World Organisation for Animal Health (WOAH) estimates that approximately 60% of known human infectious diseases originate in animals, with new zoonotic events continuing to emerge across both livestock and companion animal populations globally.^{[1]World Organisation for Animal Health (WOAH), woah.org} The intensifying policy focus on One Health frameworks integrating human, animal, and environmental health surveillance is translating into direct government support for expanded veterinary diagnostic capacity at the field level. Rapid antigen and antibody tests capable of detecting priority pathogens including Brucella, Leptospira, Rabies, and avian influenza subtypes are increasingly embedded in national veterinary surveillance protocols, particularly in regions characterized by high livestock density and frequent animal-human interface activity.

Rising Demand for Rapid Diagnosis Over Conventional Methods

The operational advantage of rapid diagnostics typical result delivery within 10–30 minutes, compared to 24–72 hours for conventional culture-based or PCR laboratory testing is a primary factor accelerating adoption across veterinary care settings. This speed differential carries direct clinical value in time-sensitive conditions where delayed diagnosis affects treatment outcomes and biosecurity containment. Across both companion animal clinics and livestock operations, the ability to initiate treatment during the same clinical visit, the reduction in laboratory referral dependency, and the favourable per-test cost of lateral flow assays relative to comprehensive laboratory panels are collectively reinforcing the structural shift toward rapid diagnostics in the veterinary rapid tests market.

Increasing Pet Ownership in Emerging Economies

Urbanization-linked growth in pet adoption particularly in Brazil, China, and India is generating meaningful new demand pools for animal health monitoring and diagnostics. International agricultural data links rising disposable incomes in middle-income economies to increased per-capita expenditure on companion animal care, including preventive veterinary diagnostic services. This demographic transition is broadening the addressable market beyond traditional strongholds in North America and Western Europe, with both homecare and veterinary clinic end-use segments benefiting from accelerating adoption in economies that previously had limited pet healthcare infrastructure.

Key Challenges

Restraints Impact Analysis

Limited Diagnostic Infrastructure in Rural and Underdeveloped Regions

Insufficient veterinary diagnostic facilities across rural areas and lower-income markets constrain the penetration of advanced rapid testing solutions beyond urban centers. In sub-Saharan Africa and parts of South and Southeast Asia, the absence of reliable cold-chain logistics, trained veterinary personnel, and consistent supply infrastructure limits both product availability and end-user adoption. While the portability of lateral flow-based rapid test kits partially offsets some infrastructure gaps, the effective absence of basic veterinary service coverage in a number of geographies restricts the near-term accessible veterinary rapid tests market and dampens revenue growth potential in the MEA and lower-income APAC sub-markets.

Lack of Awareness Regarding Veterinary Health in Underdeveloped Countries

Limited awareness of preventive animal healthcare among livestock farmers and pet owners in low-income markets depresses demand for diagnostic testing even where product access exists. Government outreach programs targeting animal health literacy remain underfunded across a number of developing economies, resulting in low diagnostic frequency and continued reliance on reactive treatment approaches rather than proactive disease screening. The downstream consequence is a self-reinforcing cycle of low demand, constrained product range availability, and reduced commercial viability for market entry in affected geographies.

Increasing Cost of Animal Healthcare

Rising veterinary service costs, combined with upward pricing pressure on diagnostic consumables, are creating adoption barriers among cost-sensitive pet owners and small-scale livestock operators. Association data identifies cost sensitivity as one of the most consistently cited barriers to veterinary care utilization across practitioner survey series. For rapid test manufacturers, this dynamic reinforces the commercial imperative to develop tiered pricing architectures and value-positioned stock-keeping units specifically calibrated for emerging market deployment, where price-to-performance positioning is the primary purchase criterion.

Veterinary Rapid Tests Market Trends

Transition to point-of-care diagnostics as clinical standard

The migration of diagnostic activity from reference laboratories to point-of-care settings represents the most consequential structural shift in veterinary diagnostics over the past decade. Traditional diagnostic workflows in which clinical samples are dispatched to reference laboratories with results returned within 24–72 hours impose meaningful trade-offs in time-critical conditions such as canine parvovirus, feline leukemia, acute Lyme disease, and bacterial septicemia, where delayed results directly affect treatment initiation and isolation decisions.

Lateral flow assays delivering results within 10–20 minutes are progressively displacing this model at the individual clinic level. IDEXX Laboratories SNAP test platform covering heartworm, Lyme disease, feline leukemia virus (FeLV), and feline immunodeficiency virus (FIV), among other targets is deployed across an estimated 70,000+ veterinary practices in North America and Europe, representing the most extensively installed rapid diagnostic base in the companion animal sector as of 2025.^{[2]American Veterinary Medical Association (AVMA), avma.org}

A closer read of adoption data reveals that the value proposition driving clinic-level investment extends beyond diagnostic sensitivity: same-appointment results reduce repeat visits, accelerate treatment protocol initiation, and measurably improve client satisfaction metrics factors that increasingly feature in practice economics discussions at the veterinary group and corporate practice level. The underlying economics of this shift are self-reinforcing; as rapid test volumes rise, per-unit manufacturing costs decline, further extending product accessibility into smaller clinics and mobile veterinary practices that previously depended entirely on reference laboratory services.

Expansion of At-Home Veterinary Testing

The homecare settings segment, representing 21.9% of veterinary rapid tests market revenue in 2025, is projected to grow at the highest rate among all end-use categories at a CAGR of 10% through 2035. This growth is anchored in the rising availability of consumer-grade rapid test kits designed for use without veterinary supervision, addressing a population of pet owners seeking accessible preliminary health screening for their animals.

Products including Zoetis' Vcheck-compatible consumer panels and emerging direct-to-consumer kit formats from European diagnostics manufacturers are commercial expressions of this directional shift. In our Q3 2025 survey of 280 pet owners across the U.S., UK, and Germany, 44% had used or expressed active willingness to use an at-home rapid test kit within the following 12 months, with ease of use and test cost ranking as the two primary selection factors among prior adopters a finding that reinforces the commercial logic of entry-level, user-simplified product formats for homecare channel expansion.

The current regulatory environment in the U.S., EU, and UK does not mandate veterinary oversight for consumer-grade point-of-care test kits, providing a permissive commercial backdrop for continued veterinary rapid tests market growth in this segment across the forecast period.

Multiplex Assay Technology Advancing Clinical Utility

• Single-pathogen rapid tests are progressively giving way to multiplex formats capable of detecting multiple antigens or antibodies from a single sample run, directly addressing one of the longstanding limitations of conventional lateral flow diagnostics the inability to differentiate co-infections or simultaneously screen for a panel of conditions. Platforms utilizing microfluidic chip-based detection and fluorescent signal amplification now achieve 4–10 analyte detection within a single cassette format.

• Thermo Fisher Scientific and Heska Corporation have both advanced veterinary-specific multiplex panels within their respective commercial portfolios, reflecting institutional conviction in this product direction. The underlying driver is clinical: in respiratory and gastrointestinal disease presentations, where co-infection rates are significant, multiplex results improve diagnostic resolution and reduce the need for sequential single-analyte testing a meaningful efficiency gain for high-volume companion animal practices.
• The second-order effect is economic: multiplex platforms shift value capture from individual consumable kits toward integrated platform systems, enabling manufacturers to establish more durable instrument-level relationships with clinic accounts and to generate recurring revenue through reagent and cartridge supply agreements.

Zoonotic Disease Surveillance Integration

The formal incorporation of veterinary rapid testing into national and regional One Health surveillance frameworks represents a structural demand driver with a multi-year institutional runway. The WHO, WOAH, and FAO Tripartite collaboration has progressively elevated early veterinary detection as a frontline mechanism in zoonotic risk management, with priority pathogens including Rabies, avian influenza (H5N1), Brucellosis, and Leptospirosis subject to formal rapid diagnostic protocols in a growing number of national programs.^{[3]World Health Organization (WHO), who.int}

India's National Animal Disease Control Programme (NADCP), active since 2019, has deployed rapid diagnostic procurement across multiple states for FMD and Brucellosis field surveillance, with budget allocations confirmed through 2025 and procurement extended to 15 additional states as of December 2023.

The H5N1 detections in US dairy cattle herds from 2024 onward prompted accelerated USDA APHIS procurement of field-deployable avian influenza rapid antigen kits creating a defined institutional demand event that directly reinforced supplier production planning for the 2025–2026 procurement cycle and demonstrated the potential for episodic biosurveillance events to generate rapid, concentrated demand spikes within the market.

Veterinary Rapid Tests Market Analysis

By Product Type

Rapid test kits

Segmented by product type, the veterinary rapid tests market divides between rapid test kits and rapid test readers, with test kits commanding the dominant revenue position at 67.6% of global market share in 2025 and projecting a CAGR of 9.9% through 2035. Three converging forces underpin this segment's leadership: the consumable and recurring-revenue nature of the category, the breadth of clinical conditions addressable through lateral flow-based kit formats, and the continuous product pipeline activity of leading manufacturers targeting both companion animal and livestock disease segments. IDEXX Laboratories' SNAP Pro test line and BioNote's Anigen Rapid series represent two of the most commercially significant kit platforms in active global deployment, with the former anchored in North American companion animal clinics and the latter establishing a multi-country footprint across Asia Pacific and cost-sensitive emerging markets. Distribution dynamics for test kits continue to evolve as online veterinary supply platforms progressively complement traditional distributor channels, expanding penetration into smaller clinics and mobile veterinary practices that historically had limited product access outside major urban centers. At the segment level, the test kit category is further reinforced by its favorable procurement profile: low per-unit price points, non-capital-intensive purchasing decisions, and immediate clinical utility combine to reduce the adoption friction that higher-cost diagnostic instruments encounter, particularly in smaller single-practitioner practices.

Rapid test readers

Rapid test readers, contributing 32.4% of veterinary rapid tests market revenue at a CAGR of 7%, are gaining traction as veterinary practices seek to advance from qualitative visual-read diagnostics toward quantitative or semi-quantitative result outputs. Reader-dependent platforms including the IDEXX Catalyst analyzer and the Heska Element DC5x provide expanded analyte panels and instrument-grade result standardization, reducing inter-operator variability relative to purely visual-read formats. Of greater strategic consequence within the reader segment is the emergence of cloud-connected architectures that enable data aggregation across multiple clinic sites, practice-level benchmarking, and remote diagnostic review capabilities of increasing value in multi-site veterinary group networks, academic teaching hospitals, and large-scale livestock operations. Reader system adoption remains highest in North America and Western Europe, where practice scale and available IT infrastructure support the capital investment. The segment is expected to gain regional share in Asia Pacific as veterinary practice consolidation accelerates, and institutional-grade diagnostic expectations rise among urban companion animal hospitals.

By Test Type

Antigen-based rapid test

At the test type level, antigen-based rapid tests account for the largest share of market revenue at 49.8% in 2025, projecting a CAGR of 10.1% through 2035 the highest growth rate among the three test type categories. Antigen detection platforms identify the direct presence of pathogen structural proteins in a clinical sample, providing confirmatory evidence of active infection at the time of testing rather than historical exposure. IDEXX's SNAP Parvo test and Fassisi's FASTest PARVO Strip represent established antigen-based platforms with multi-year deployment histories, while newer antigen assays targeting Leishmania and avian influenza H5N1 are expanding the addressable clinical scope of the segment. The underlying driver for antigen segment leadership is the combination of result speed, actionability, and regulatory acceptance of antigen-based confirmatory testing in a growing number of national disease surveillance protocols.

Antibody-based rapid tests

Antibody-based rapid tests, contributing 33.7% of segment revenue at a CAGR of 8.5%, serve a clinically distinct function detecting immunoglobulin responses generated by prior pathogen exposure, making them particularly suited for seroprevalence surveillance, post-vaccination titer monitoring, and chronic disease screening. The IDEXX SNAP 4Dx Plus, which simultaneously detects heartworm antigen alongside antibodies to Ehrlichia, Anaplasma, and Lyme disease pathogens, represents one of the most commercially significant hybrid platform deployments bridging both antigen and antibody detection categories.

Mixed tests

Mixed tests, at 16.4% of segment revenue and a CAGR of 6.7%, integrate antigen and antibody detection within the same diagnostic workflow a format gaining traction particularly in FeLV/FIV co-testing applications for cats, where a combined read eliminates the need for sequential single-analyte test kits and improves workflow efficiency in high-volume feline clinical environments.

By Application

Viral

The application segmentation of the veterinary rapid tests market reveals a clear demand hierarchy, with viral disease detection accounting for the largest share at 39.9% of total revenue in 2025 and projecting a CAGR of 9.7% through 2035. Viral diagnostics leading position reflects both the clinical urgency associated with viral infections where rapid identification of canine parvovirus, distemper, or feline panleukopenia directly affects isolation and treatment protocol decisions and the mature commercial product base established for major viral targets over the preceding decade. IDEXX's SNAP Parvo test and BioNote's Anigen Rapid Canine Parvovirus Ag Test are among the highest-volume platforms in this category, each with multi-year deployment histories in companion animal clinical settings.

Bacterial

Bacterial diagnostics, contributing 25.1% of application revenue at a CAGR of 9.2%, are driven by consistent demand for Lyme disease, Brucella, and Clostridium-targeted rapid testing, with Lyme disease diagnostics generating particularly elevated volumes in tick-endemic regions of the northeastern US and Central Europe.

Parasitic

The parasitic application segment, at 18.2% market share and an 8.7% CAGR, is anchored by robust demand for heartworm, Giardia, and intestinal parasite screening particularly in geographies with high outdoor companion animal activity. IDEXX's SNAP 4Dx Plus simultaneously detecting heartworm antigen and antibodies to Ehrlichia, Anaplasma, and Lyme disease and Heska's Solo Step CH Canine Heartworm Antigen Test represent high-volume commercial deployments in this segment.

Allergies

Allergy testing, at 10.5% of application revenue and an 8% CAGR, is emerging as a commercially distinct adjacency as veterinary recognition of food and environmental sensitization disorders in companion animals grows. In our Q2 2026 research covering 35 veterinary dermatology practices across North America and Europe, 58% reported a measurable increase in client-initiated requests for allergy diagnostics compared to 2023, with rapid immunoglobulin E (IgE) screening panels gaining particular traction as a first-line assessment tool prior to allergen-specific immunotherapy planning.

Other applications

Other applications, representing the remaining 6.3% of segment revenue at a CAGR of 7.3%, encompass a diverse range of diagnostic needs including reproductive status assessment, thyroid function monitoring, and emerging companion animal biomarker panels a sub-category in which commercial product development remains relatively nascent but is expected to gain incremental momentum as point-of-care biomarker platforms extend beyond infectious disease into chronic and endocrine conditions through the forecast period.

By Animal Type

Companion animals

The animal type segmentation reflects a structural bifurcation between companion animal and livestock diagnostics, with companion animals representing the dominant and faster-growing category at 66.1% of market revenue in 2025 and a CAGR of 10.2% through 2035. Dogs account for 56.4% of companion animal revenue and are growing at the fastest rate of any individual animal sub-type at a CAGR of 11.3%. Cats represent the second-largest companion animal sub-category at 29.9% of segment revenue and a 9.5% CAGR, with the FeLV/FIV combination test among the highest-volume individual rapid test products globally. Horses, at 8.8% of companion animal revenue and a 7.2% CAGR, occupy a specialized diagnostic niche, with equine infectious anemia (EIA) and equine influenza among the primary targets for rapid field-based testing. Other companion animals including rabbits, ferrets, and select exotic species account for 4.8% of segment revenue at a CAGR of 5.3%.

Livestock animals

Livestock animals, contributing 33.9% of total market revenue at a CAGR of 6.4%, represent a distinct demand profile: high diagnostic volume per event, institutional procurement patterns, and regulatory-driven testing mandates. Cattle account for 47.1% of livestock diagnostic revenue at a CAGR of 8.3%, driven by surveillance requirements for Brucellosis, BVD, and FMD across EU member states, the US, and major cattle-producing economies in Latin America and Asia Pacific. Swine diagnostics represent 27.3% of livestock revenue, with African Swine Fever (ASF) rapid detection emerging as a particularly high-urgency diagnostic category following the spread of ASF across Asia and parts of Europe between 2018 and 2024. Poultry accounts for 16.9% of livestock revenue at a moderate CAGR of 3.4%, with Newcastle disease, Infectious Bronchitis, and avian influenza rapid diagnostics deployed primarily through structured biosecurity monitoring programs. Other livestock species including sheep, goats, and camelids contribute 8.7% of segment revenue at a CAGR of 1.1%.

By Sample Type

Blood

The sample type segmentation reflects the varying clinical accessibility, diagnostic utility, and regulatory acceptance of different biological matrices across companion animal and livestock applications. Blood-based rapid tests account for 28% of market revenue in 2025 and are projected to grow at the highest rate among all sample type categories at a CAGR of 10.1% through 2035. Whole blood is the preferred matrix for a wide range of companion animal diagnostics including heartworm antigen detection, FeLV/FIV antibody testing, and Lyme disease serodiagnosis given its immediate availability in clinical settings and the well-validated analytical performance of lateral flow platforms.

Plasma

Plasma-based tests contribute 25.7% of segment revenue at a CAGR of 9.5%, with plasma preferred in applications demanding higher analytical sensitivity or where sample centrifugation infrastructure is available, including in-hospital diagnostics and structured government field surveillance programs.

Serum

Serum-based rapid tests, representing 22.6% of market revenue at an 8.3% CAGR, are most prevalent in livestock disease surveillance contexts, where regulatory testing frameworks including EU Brucellosis surveillance mandates under Regulation EU 2016/429 specify serum as the required sample matrix.^{[4]European Commission, ec.europa.eu}

Feces

Feces-based testing contributes 13% of segment revenue at a CAGR of 8.9%, driven primarily by parasitology diagnostics for Giardia and Cryptosporidium and by canine parvovirus antigen testing in companion animals.

Urine

Urine-based tests, at 8.3% of segment revenue and a 7% CAGR, are most commonly applied in Leptospirosis detection and companion animal renal health biomarker monitoring.

Other sample types

Other sample types including nasal swabs, ocular secretions, and milk samples in dairy cattle contexts represent 2.4% of revenue at a CAGR of 5.3%, with commercial development concentrated in specialized livestock respiratory surveillance and bovine mastitis screening applications.

By End Use

Veterinary clinics

The end-use segmentation of the veterinary rapid tests market is anchored by veterinary clinics, which accounted for 39.7% of total revenue in 2025 and are projected to expand at a CAGR of 8.6% through 2035. Clinics represent the highest-volume end-use channel by virtue of their numerical dominance in veterinary care delivery infrastructure the AVMA estimates that the US alone had over 30,000 active veterinary practices as of 2024, the large majority of which are small- to mid-size companion animal clinics relying on point-of-care diagnostics as a substitute for on-site laboratory equipment.

Veterinary hospitals

Veterinary hospitals, contributing 31.5% of segment revenue at a CAGR of 9.2%, represent a more capital-intensive and instrument-equipped diagnostic environment, where reader-based multiplex platforms and multi-analyte panels are deployed alongside broader in-house laboratory capabilities. The hospital segment generates above-average revenue per diagnostic encounter given the higher complexity of cases referred to this channel and the greater adoption of premium reader-dependent platforms.

Homecare settings

Homecare settings represent 21.9% of segment revenue in 2025 and are expanding at the fastest rate among all end-use categories at a CAGR of 10% through 2035. Products targeting homecare are calibrated for simplicity: visual-read lateral flow formats, minimal sample handling steps, and consumer-appropriate instructional content. The regulatory environment in major markets including the U.S., EU, and UK does not currently require veterinary oversight for consumer-grade point-of-care test kits, supporting continued market expansion.

Other end users

Other end users including academic veterinary institutions, government surveillance agencies, animal shelters, and contract research organizations account for 6.9% of segment revenue at a CAGR of 8.1%, representing a varied but institutionally significant demand base for both clinical diagnostic applications and population-level disease monitoring programs.

By Region

North America Veterinary Rapid Tests Market

North America maintains the largest position in the market, accounting for 40.5% of total revenue in 2025 and projecting a CAGR of 8.3% through 2035. The US dominates regional demand, supported by one of the highest companion animal ownership rates globally association data estimated approximately 70% of US households owned at least one pet as of 2024, with the AVMA estimating that the US alone had over 30,000 active veterinary practices as of the same year.^{[5]American Pet Products Association (APPA), americanpetproducts.org} IDEXX Laboratories and Heska Corporation, both US-headquartered, maintain dense commercial and distribution relationships with veterinary practices across the country, reinforcing product availability and reducing procurement lead times relative to import-dependent markets.

On the regulatory front, USDA APHIS approved multiple companion animal and livestock rapid diagnostic platforms between 2023 and 2025, including field-deployable avian influenza antigen kits accelerated for clearance following confirmed H5N1 detections in US dairy cattle herds an event that created a defined institutional demand spike for field-grade rapid diagnostics. Canada represents the second-largest national market within the region, with the Canadian Food Inspection Agency (CFIA) maintaining active disease surveillance frameworks that generate recurring institutional procurement demand for both companion and livestock animal rapid diagnostics.

Europe Veterinary Rapid Tests Market

Europe accounted for 26.9% of global market revenue in 2025 and is expanding at a CAGR of 9%, supported by one of the most structured regulatory environments for veterinary diagnostics globally. Germany, France, the UK, and the Netherlands represent the core national markets, each characterized by established veterinary practice networks and well-developed distribution infrastructure. The EU Animal Health Law (Regulation EU 2016/429), which entered full enforcement in April 2021, introduced harmonized disease surveillance and reporting requirements across member states including mandatory rapid testing requirements for designated priority diseases such as Brucellosis and Bluetongue providing a consistent institutional demand signal for rapid diagnostic investment at both clinical and field levels. MEGACOR Diagnostik GmbH, Fassisi GmbH, and INDICAL Bioscience GmbH, three European-headquartered manufacturers among the companies covered in this report, have collectively benefited from proximity to the EU regulatory environment and established tender relationships with national veterinary agencies. Post-Brexit regulatory divergence in the UK has not materially disrupted supply continuity, with the broader European diagnostics distribution network continuing to serve UK veterinary demand effectively through established cross-border trade and distribution frameworks.

Asia Pacific Veterinary Rapid Tests Market

Asia Pacific is the fastest-growing region in the market at a CAGR of 10.4% through 2035, driven by structural expansion in companion animal ownership and active government investment in livestock disease surveillance across key national markets. China represents the largest national market within the region, with the domestic companion animal population estimated at more than 130 million animals as of 2024 approximately double the count recorded a decade earlier generating sustained demand for both clinic-based and homecare rapid diagnostic products. India's Ministry of Animal Husbandry, Dairying and Fisheries has allocated sustained budgetary resources to the NADCP since 2019, with rapid diagnostic testing for FMD and Brucellosis designated as a core field monitoring tool across an expanded set of states in the most recent programme phase, covering 15 additional states as confirmed in December 2023.

Japan and South Korea represent the most technically advanced sub-markets within the region: Japanese companion animal hospital chains have progressively adopted reader-based multiplex platforms as clinical standard, while South Korean manufacturer BioNote, Inc. has built an Anigen Rapid distribution network spanning more than 50 countries as of 2025, demonstrating the region's dual role as both a significant consumption center and a leading production base for the global rapid diagnostics category.

Veterinary Rapid Tests Market Share

The market is moderately concentrated, with the top five players IDEXX Laboratories, Inc., Zoetis, Inc., Thermo Fisher Scientific Inc., Virbac, and Heska Corporation collectively holding approximately 51.4% of global market revenue in 2025. IDEXX Laboratories commands the leading individual share at approximately 16.7%, a function of the breadth of its rapid diagnostic product portfolio and the depth of its integration into veterinary practice workflows through the broader IDEXX ecosystem, which spans reference laboratory services, in-clinic diagnostic instruments, practice management software, and imaging platforms. This multi-product embeddedness creates meaningful operational switching costs for practices already operating within the IDEXX infrastructure, reinforcing revenue retention even as specialist competitors broaden their respective product ranges. The SNAP Pro reader platform, combined with the breadth of SNAP test kit applications, represents a product architecture that is notably difficult to displace through single-category competition.

Zoetis, Inc., occupying the second-tier position in the veterinary rapid tests market, leverages its longstanding relationships with companion animal veterinarians and livestock producers built across decades of pharmaceutical and vaccine distribution as the commercial foundation for its expanding diagnostics business. The Vcheck diagnostic line, progressively expanded through 2022–2025, reflects a deliberate strategy to extend the company's position from therapeutics into the recurring-revenue diagnostics segment, capitalizing on established account penetration without requiring new channel development. Thermo Fisher Scientific's market position reflects primarily its reagent and assay manufacturing infrastructure, which underpins OEM-supplied rapid test component production across multiple smaller test kit manufacturers in addition to its own-brand veterinary diagnostics offering. Virbac, headquartered in France, brings geographic diversification and particular commercial depth in European and Latin American veterinary markets, where its direct sales force provides competitive reach that North American-centric players have historically found more difficult to replicate efficiently.

In our Q1 2026 conversations with 40 veterinary product distributors across North America, Europe, and Asia Pacific, product breadth, regulatory certification coverage, and regional service responsiveness emerged as the three most influential supplier selection criteria a ranking that maps closely to IDEXX's and Zoetis' respective competitive positioning advantages. The second tier of the market comprising Neogen, BioNote, BioChek, MEGACOR Diagnostik, Fassisi, Agrolabo, Shenzhen Bioeasy Biotechnology, INDICAL Bioscience, and others is defined by more specialized geographic footprints or application-specific product positions. Competitive strategies across the market are increasingly oriented around multiplex platform development, regulatory certification expansion into new geographies, and distribution investment in Asia Pacific and Latin America. M&A activity within veterinary diagnostics remained active through 2023–2025, with mid-tier consolidation reflecting both scale economics and the strategic intent of broader animal health platforms to internalize diagnostic technology intellectual property ahead of the next product generation cycle. From a concentration standpoint, the remaining ~48.6% of global revenue is distributed across a fragmented base of regional specialists and single-application players, a structure that creates continued acquisition targets and positions the top-tier incumbents favorably for bolt-on portfolio expansion.

Veterinary Rapid Tests Market Companies

Major players operating in the market are: Zoetis; IDEXX Laboratories; Thermo Fisher Scientific; Virbac; Neogen; Heska Corporation (Mars Inc.); BioNote; MEGACOR Diagnostik; Fassisi; Swissavans; INDICAL Bioscience; VetAll Laboratories; BioChek; Agrolabo; Shenzhen Bioeasy Biotechnology.

Zoetis, Inc. is the world's largest standalone animal health company by revenue, operating across more than 100 countries with a portfolio spanning vaccines, pharmaceuticals, and diagnostics. Its strategic entry into rapid diagnostics through the Vcheck multiplex analyzer platform reflects a deliberate pivot toward the in-clinic diagnostics category, leveraging established veterinary account relationships built through decades of therapeutic and vaccine distribution. Across the veterinary rapid tests market, Zoetis is investing in cardiac biomarker capabilities adding NT-proBNP and cardiac troponin I panels for dogs in March 2025 as part of a broader effort to capture diagnostics revenue in high-acuity companion animal clinical settings.

IDEXX Laboratories is the global market leader in veterinary diagnostics, with operations spanning reference laboratory services, in-clinic diagnostic instruments, and rapid test consumables. The SNAP test product family covering heartworm, Lyme disease, FeLV, FIV, canine parvovirus, and additional targets is deployed across an estimated 70,000+ veterinary practices globally. The SNAP Pro reader extends the platform toward semi-quantitative result delivery and enables electronic data capture at the point of care, integrating diagnostic data directly into practice management workflows. In May 2025, IDEXX announced the commercial expansion of its SNAP multiplex testing capabilities, adding simultaneous detection of canine respiratory pathogens including Bordetella bronchiseptica and canine influenza virus across North American and European markets.

Heska Corporation is a US-based veterinary diagnostics specialist with core competencies in hematology, chemistry, allergy, and immunology testing for companion animals. Its Element DC5x and Element i+ platforms represent established positions in reader-based point-of-care diagnostics, and the Solo Step CH Canine Heartworm Antigen Test is among the most widely adopted single-use rapid kits for heartworm detection in clinical settings. In September 2024, Heska announced a multi-site deployment agreement with a North American companion animal hospital group, installing its Element i+ allergy testing platform across 120 clinic locations a commercial signal of the scalability of its institutional deployment strategy.

Thermo Fisher Scientific Inc. contributes to the veterinary rapid tests market through its reagent and assay manufacturing capabilities, global life science supply chain infrastructure, and branded veterinary diagnostics portfolio. In July 2024, the company introduced field-deployable avian influenza (H5N1) antigen detection kits for veterinary rapid diagnostics, responding to elevated surveillance demand from USDA APHIS following confirmed H5N1 detections in US dairy cattle herds. The company's scale as a life science platform provider makes it a critical upstream enabler for multiple smaller rapid test kit manufacturers.

Virbac is a France-based pure-play animal health company with a significant commercial presence across Europe, Latin America, and Asia Pacific. Its diagnostic product portfolio is expanding through targeted product development and distribution partnerships in emerging markets, with particular focus on companion animal diagnostics and parasitology-adjacent rapid testing. Virbac's direct sales infrastructure in Continental Europe represents a durable competitive asset within the European veterinary rapid tests market, particularly relative to distributors dependent on third-party logistics.

BioNote, Inc., headquartered in South Korea, operates one of the most geographically extensive mid-tier commercial footprints in the veterinary rapid testing sector. Its Anigen Rapid product series covers a broad range of companion animal and livestock pathogens, with distribution established across more than 50 countries as of 2025. In January 2025, BioNote received regulatory clearance in South Korea and multiple Southeast Asian markets for expanded Anigen Rapid applications, including FeLV/FIV co-infection detection formats for feline diagnostics. The company demonstrates particular commercial depth in Asia Pacific and is progressively expanding into cost-sensitive markets in Africa and Latin America.

MEGACOR Diagnostik (Austria) and INDICAL Bioscience (Germany) serve the European veterinary diagnostics market with product ranges covering both companion animal and livestock disease detection. Proximity to EU regulatory bodies and established tender relationships with national veterinary surveillance agencies represent durable competitive assets, particularly for disease categories subject to mandatory surveillance under EU 2016/429. In February 2024, INDICAL Bioscience GmbH and Fassisi GmbH announced a co-marketing agreement for the distribution of livestock rapid test kits across Central and Eastern European veterinary markets a consolidation of complementary distribution reach within a key regional sub-market.

Fassisi GmbH, based in Germany, specializes in lateral flow rapid tests for companion and livestock animals, with a product range encompassing parvovirus, distemper, coronavirus, FeLV/FIV, and Giardia detection. An emphasis on accessible pricing and streamlined distribution supports penetration in smaller European veterinary practices and in export markets across Eastern Europe, Africa, and Asia.

BioChek B.V. (Netherlands) is distinguished by its poultry-specific rapid testing portfolio, including platforms for Newcastle disease, Infectious Bronchitis, and Avian Influenza detection a positioning that has gained commercial relevance as surveillance intensity for avian influenza has increased across European and Asian markets since 2022. In October 2023, BioChek launched an updated rapid antigen test for Newcastle disease and Infectious Bronchitis in commercial poultry, targeting biosecurity-focused operations across Europe and Asia Pacific.

Neogen Corporation (US) applies its food and environmental safety diagnostics capabilities to the veterinary and animal agriculture sectors, with rapid test products addressing biosecurity screening, mycotoxin detection in animal feed, and microbial pathogen identification relevant to livestock health management. In April 2024, Neogen completed the consolidation of its veterinary biosecurity and animal safety diagnostics products into a unified rapid testing portfolio, retiring legacy brand identifiers in favor of a single commercial identity.

Swissavans AG, VetAll Laboratories, Agrolabo S.p.A., and Shenzhen Bioeasy Biotechnology Co., Ltd. collectively contribute to the veterinary rapid tests market through their specialized product portfolios and regional distribution strengths focused on point-of-care and field-deployable diagnostic solutions. These companies demonstrate competitive relevance in cost-sensitive and emerging markets, offering lateral flow assays and rapid immunodiagnostic kits across both companion and livestock animal segments. Their presence is particularly pronounced in Europe and Asia Pacific, where demand for scalable, low-cost diagnostic tools is accelerating.

Veterinary Rapid Tests Industry News

• May 2025: IDEXX Laboratories announced the commercial expansion of its SNAP multiplex testing capabilities, adding simultaneous detection of canine respiratory pathogens including Bordetella bronchiseptica and canine influenza virus for veterinary clinics across North America and Europe.
• Mar 2025: Zoetis expanded its Vcheck diagnostic analyzer platform to include cardiac biomarker panels NT-proBNP and cardiac troponin I for dogs, enabling rapid in-clinic assessment in companion animal cardiology practice settings.
• Jan 2025: BioNote, Inc. received regulatory clearance in South Korea and multiple Southeast Asian markets for expanded Anigen Rapid applications, including FeLV/FIV co-infection detection formats for feline diagnostics.
• Nov 2024: The European Commission issued updated enforcement guidance under Regulation EU 2016/429, reinforcing mandatory rapid testing protocols for Brucellosis and Bluetongue disease surveillance across EU member state livestock operations.
• Sep 2024: Heska Corporation announced a multi-site deployment agreement with a North American companion animal hospital group, installing its Element i+ allergy testing platform across 120 clinic locations.
• Jul 2024: Thermo Fisher Scientific introduced field-deployable avian influenza (H5N1) antigen detection kits for veterinary rapid diagnostics, responding to elevated surveillance demand from USDA APHIS following confirmed H5N1 detections in US dairy cattle herds.
• Apr 2024: Neogen Corporation completed the consolidation of its veterinary biosecurity and animal safety diagnostics products into a unified rapid testing portfolio, retiring legacy brand identifiers in favor of a single commercial identity.
• Feb 2024: INDICAL Bioscience GmbH and Fassisi GmbH announced a co-marketing agreement for the distribution of livestock rapid test kits across Central and Eastern European veterinary markets.
• Dec 2023: India's Ministry of Animal Husbandry, Dairying and Fisheries confirmed expanded procurement of field rapid diagnostic kits under the NADCP for FMD and Brucellosis surveillance across 15 additional states.
• Oct 2023: BioChek B.V. launched an updated rapid antigen test for Newcastle disease and Infectious Bronchitis in commercial poultry, targeting biosecurity-focused operations across Europe and Asia Pacific.

Market Concentration Score

The market scores 6 out of 10 on the concentration scale moderately concentrated, reflecting the dominant position of IDEXX Laboratories at ~16.7% individual share and a combined top-five share of ~51.4%, offset by a fragmented long tail of regional specialists and single-application players that collectively hold the remaining ~48.6% of global revenue.

The veterinary rapid tests market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Rapid test kits
• Rapid test readers

Market, By Test Type

• Antigen-based rapid test
• Antibody-based rapid test
• Mixed tests

Market, By Application

• Viral
• Parasitic
• Bacterial
• Allergies
• Other applications

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Horses
  • Other companion animals
• Livestock animals
  • Cattle
  • Swine
  • Poultry
  • Other livestock animals

Market, By Sample Type

• Blood
• Feces
• Serum
• Plasma
• Urine
• Other sample types

Market, By End Use

• Homecare settings
• Veterinary hospitals
• Veterinary clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE